Steffen Frese

Summary

Affiliation: University of Konstanz
Country: Germany

Publications

  1. ncbi request reprint PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
    Steffen Frese
    Department of Clinical Research, Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    Oncogene 22:5427-35. 2003
  2. ncbi request reprint Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne and The Tiefenau Laboratory, Department of Clinical Research, University of Berne, Switzerland
    Cancer Res 66:5867-74. 2006
  3. doi request reprint Structural modification of DNA--a therapeutic option in SLE?
    Steffen Frese
    Department of Clinical Research, University Hospital Bern, Murtenstrasse 50, P O Box 44, CH 3010 Bern, Switzerland
    Nat Rev Rheumatol 7:733-8. 2011
  4. doi request reprint Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5
    Manuela Frese-Schaper
    Department of Clinical Research, University of Bern, Bern, Switzerland
    FEBS Lett 584:2867-71. 2010
  5. ncbi request reprint Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage
    Steffen Frese
    Division of General Thoracic Surgery, Department of Clinical Research, University Hospital, Murtenstrasse 35, Room C807, CH 3010 Berne, Switzerland
    J Thorac Cardiovasc Surg 126:748-54. 2003
  6. ncbi request reprint Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer
    Steffen Frese
    Laboratory of Thoracic Surgery, University Hospital Bern, Murtenstrasse 35 room C807, CH 3010 Berne, Switzerland
    Anticancer Res 29:2905-11. 2009
  7. ncbi request reprint Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitor
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    J Thorac Cardiovasc Surg 123:168-74. 2002
  8. doi request reprint Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan
    Manuela Frese-Schaper
    Department of Clinical Research, University Hospital Bern, Bern, Switzerland
    J Immunol 184:2175-82. 2010
  9. ncbi request reprint Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver
    Jan Plock
    Clinic of Visceral and Transplantation Surgery, Department of Clinical Research, University of Bern, Murtenstrase 35, 3010 Bern, Switzerland
    J Hepatol 47:538-45. 2007
  10. ncbi request reprint A large mediastinal tumor with spontaneous regression 30 years after esophageal bypass surgery
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    Ann Thorac Surg 74:1711-2. 2002

Collaborators

Detail Information

Publications13

  1. ncbi request reprint PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
    Steffen Frese
    Department of Clinical Research, Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    Oncogene 22:5427-35. 2003
    ..In conclusion, apoptosis induced by the combination of Apo2L/TRAIL and PG490 warrants further evaluation as a potential new strategy for the treatment of lung cancer...
  2. ncbi request reprint Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne and The Tiefenau Laboratory, Department of Clinical Research, University of Berne, Switzerland
    Cancer Res 66:5867-74. 2006
    ..Our data suggest that the combination of Apo2L/TRAIL and cardiac glycosides may be a new interesting anticancer treatment strategy...
  3. doi request reprint Structural modification of DNA--a therapeutic option in SLE?
    Steffen Frese
    Department of Clinical Research, University Hospital Bern, Murtenstrasse 50, P O Box 44, CH 3010 Bern, Switzerland
    Nat Rev Rheumatol 7:733-8. 2011
    ....
  4. doi request reprint Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5
    Manuela Frese-Schaper
    Department of Clinical Research, University of Bern, Bern, Switzerland
    FEBS Lett 584:2867-71. 2010
    ..In conclusion, inhibition of tissue transglutaminase provides an interesting strategy for sensitization to TRAIL-induced apoptosis in p53-deficient lung cancer cells...
  5. ncbi request reprint Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage
    Steffen Frese
    Division of General Thoracic Surgery, Department of Clinical Research, University Hospital, Murtenstrasse 35, Room C807, CH 3010 Berne, Switzerland
    J Thorac Cardiovasc Surg 126:748-54. 2003
    ..We therefore evaluated whether selective depletion of heat shock protein 70 induces cell death in lung cancer cells...
  6. ncbi request reprint Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer
    Steffen Frese
    Laboratory of Thoracic Surgery, University Hospital Bern, Murtenstrasse 35 room C807, CH 3010 Berne, Switzerland
    Anticancer Res 29:2905-11. 2009
    ..The aim of the present study was the evaluation of these results in a model of primary culture of non-small cell lung cancer...
  7. ncbi request reprint Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitor
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    J Thorac Cardiovasc Surg 123:168-74. 2002
    ..In addition, endogenous expression levels of the caspase-inhibiting cellular protease caspase-8 inhibitory protein (C-FLIP) were measured to investigate partial resistance to Apo2L/TRAIL...
  8. doi request reprint Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan
    Manuela Frese-Schaper
    Department of Clinical Research, University Hospital Bern, Bern, Switzerland
    J Immunol 184:2175-82. 2010
    ..In conclusion, our data provide evidence that irinotecan might represent an entirely new strategy for the treatment of systemic lupus erythematosus...
  9. ncbi request reprint Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver
    Jan Plock
    Clinic of Visceral and Transplantation Surgery, Department of Clinical Research, University of Bern, Murtenstrase 35, 3010 Bern, Switzerland
    J Hepatol 47:538-45. 2007
    ..We investigated the molecular response of a non-ischemic hypoxic stress in the liver, in particular, to distinguish its hepatoprotective potential...
  10. ncbi request reprint A large mediastinal tumor with spontaneous regression 30 years after esophageal bypass surgery
    Steffen Frese
    Division of General Thoracic Surgery, University Hospital Berne, Switzerland
    Ann Thorac Surg 74:1711-2. 2002
    ..Seven days after admission a chest roentgenogram showed almost complete regression of the tumor, which was supposed to be a mucocele of the colon bypassing the esophagus...
  11. ncbi request reprint Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples
    Farzaneh Pirnia
    Institute of Medical Oncology, University of Bern, Inselspital, Bern, Switzerland
    Anticancer Res 26:1765-72. 2006
    ..One of the few possible approaches is serial biopsies in patients. However, this type of research is severely limited by methodological and ethical constraints...
  12. pmc TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality
    Nadia Corazza
    Division of Immunopathology, Institute of Pathology, University of Bern, Bern, Switzerland
    J Clin Invest 116:2493-9. 2006
    ..We conclude that TRAIL and Bim are important response modifiers of hepatocyte apoptosis and identify liver damage and lethality as a possible risk of TRAIL-based tumor therapy...
  13. pmc Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
    Kazuyoshi Takeda
    Department of Immunology, Juntendo University School of Medicine, Hongo 2 1 1, Bunkyo ku, Tokyo 113 8421, Japan
    Proc Natl Acad Sci U S A 105:10895-900. 2008
    ..Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis...